Contents

Current Cancer Drug Targets, Volume 11 - Number 1

Editorial [Hot topic: Special Edition Myeloproliferative Neoplasia – Disease Pathogenesis and Treatment Options (Guest Editors: D. Wolf and H. Rumpold)]

, 11(1): 1 - 2

Dominik Wolf and H. Rumpold


DOI: 10.2174/156800911793743646




Molecular Pathogenesis of Philadelphia-Positive Chronic Myeloid Leukemia – is it all BCR-ABL?

, 11(1): 3 - 19

H. Rumpold and G. Webersinke


DOI: 10.2174/156800911793743619




Molecular Pathogenesis of Philadelphia Chromosome Negative Chronic Myeloproliferative Neoplasms

, 11(1): 20 - 30

R. Jager and R. Kralovics


DOI: 10.2174/156800911793743628




Current Treatment Concepts of CML

, 11(1): 31 - 43

A. A. Leitner, A. Hochhaus and M. C. Muller


DOI: 10.2174/156800911793743637




Current Treatment Concepts of Philadelphia-Negative MPN

, 11(1): 44 - 55

D. Wolf, J. Rudzki and G. Gastl


DOI: 10.2174/156800911793743592




Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept

, 11(1): 56 - 71

P. Valent


DOI: 10.2174/156800911793743655




Immunotherapy for Myeloproliferative Neoplasms (MPN)

, 11(1): 72 - 84

Susanne Hofmann, Anna Babiak and Jochen Greiner


DOI: 10.2174/156800911793743682




Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives

, 11(1): 85 - 102

S. Cecco, E. Muraro, E. Giacomin, D. Martorelli, R. Lazzarini, P. Baldo and R. Dolcetti


DOI: 10.2174/156800911793743664




Chronic Vaccination with a Therapeutic EGF-Based Cancer Vaccine: A Review of Patients Receiving Long Lasting Treatment

, 11(1): 103 - 110

G. Gonzalez, T. Crombet and A. Lage


DOI: 10.2174/156800911793743583




High Therapeutic Potential for Systemic Delivery of a Liposomeconjugated Herpes Simplex Virus

, 11(1): 111 - 122

T. Shikano, H. Kasuya, T. T. Sahin, N. Nomura, A. Kanzaki, M. Misawa, Y. Nishikawa, T. Shirota, S. Yamada, T. Fujii, H. Sugimoto, N. Kanazumi, S. Nomoto, S. Takeda and A. Nakao


DOI: 10.2174/156800911793743673




Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)

, 11(1): 123 - 129

D. Santini, G. Schiavon, B. Vincenzi, C. E. Cass, E. Vasile, A. D. Manazza, V. Catalano, G. G. Baldi, R. Lai, S. Rizzo, A. Giacobino, L. Chiusa, M. Caraglia, A. Russo, J. Mackey, A. Falcone and G. Tonini


DOI: 10.2174/156800911793743600




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science